FDA
Breakthrough Device Designation

Noninvasive Hemodynamic Insight for Heart Failure Care

Coredio estimates catheter grade intracardiac hemodynamics using wearables, AI, and digital twins 

The Challenge

Cardiac monitoring today is fragmented, costly , and invasive

Insufficient Monitoring

Current standard of care is either non-existent or inaccurate for effective heart failure management

Limited Access Between Visits

Care team dont have access to echocardiograms or catheterizations to get accurate hemodynamic status.

Invasive &
Costly

Accurate insight at-home or out-patient is only available through costly and invasive implantables.

The Challenge

Cardiac monitoring today is fragmented, costly , and invasive

Insufficient Monitoring

Current standard of care is either non-existent or inaccurate for effective heart failure management

Limited Access Between Visits

Care team dont have access to echocardiograms or catheterizations to get accurate hemodynamic status.

Invasive & Costly

Accurate insight at-home or out-patient is only available through costly and invasive implantables.

Join the clinicians who are exploring the future of cardiovascular monitoring

Connect
with Coredio team

FDA

Disclaimer: Coredio CPSE™ has received FDA Breakthrough Device Designation. The device is not yet cleared by the FDA for commercial use. Indications for Use are subject to FDA review under the 510(k) process.

FDA

Disclaimer: Coredio CPSE™ has received FDA Breakthrough Device Designation. The device is not yet cleared by the FDA for commercial use. Indications for Use are subject to FDA review under the 510(k) process.